CD274 and neoplasm: Since 2017, Pembrolizumab can be applied as first-line systemic therapy for patients with PD-L1 expression in cancer cells >50 % or as a second-line systemic therapy after progression on first-line chemotherapy, with at least 1 % PD-L1 expression in tumor cells.